<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MAEKURA, TOSHIYA</style></author><author><style face="normal" font="default" size="100%">NAITO, MAIKO</style></author><author><style face="normal" font="default" size="100%">TAHARA, MASAHIRO</style></author><author><style face="normal" font="default" size="100%">IKEGAMI, NAOYA</style></author><author><style face="normal" font="default" size="100%">KIMURA, YOHEI</style></author><author><style face="normal" font="default" size="100%">SONOBE, SHOKO</style></author><author><style face="normal" font="default" size="100%">KOBAYASHI, TAKEHIKO</style></author><author><style face="normal" font="default" size="100%">TSUJI, TAISUKE</style></author><author><style face="normal" font="default" size="100%">MINOMO, SHOJIRO</style></author><author><style face="normal" font="default" size="100%">TAMIYA, AKIHIRO</style></author><author><style face="normal" font="default" size="100%">ATAGI, SHINJI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1035-1039</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. Patients and Methods: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed. Results: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism. Conclusion: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism.</style></abstract></record></records></xml>